Abstract
Twenty-five years ago over 90% of children with acute lymphoblastic leukaemia (ALL) died of this disease. Dramatic improvement has been achieved since then by employing risk-adapted, aggressive polychemotherapy protocols. More than 90% of children with ALL treated according to, for example BFM-protocols, have nowadays cure rates in the range of 70%–80%. However, 10% of patients do not initially respond adequately to standard induction chemotherapy. They are characterized by distinct chromosomal abnormalities such as translocation (9; 22) or combinations of early treatment failure and other risk factors as cytogenetic abnormalities, lineage-specific surface markers or tumour load at diagnosis. In this group of patients in first complete remission and certainly in the vast majority of relapsed patients, allogeneic bone marrow transplantation (BMT) has evolved as an alternative approach allowing further intensification of myeloablation and the introduction of an additional antileukaemic alloreactivity. Nevertheless, the decision for a marrow transplant in children has to be made very carefully because of a significant increase in treatment related mortality and BMT-specific risks like acute and chronic graft-versus-host disease with a critical iatrogenic chronic morbidity. This is even more evident, if mismatched or unrelated transplants are being considered. The indications for one or the other treatment modality according to the current BFM strategy are discussed.
Similar content being viewed by others
Abbreviations
- ALL:
-
acute lmyphoblastic leukaemia
- BFM:
-
German/Austrian co-operative group for the treatment of childhood leukaemias, originally named after the founding centres in Berlin-Frankfurt-Münster
- BMT:
-
bone marrow transplantation
- EFS:
-
event free survival according to life table analysis (Kaplan-Mejer analysis)
- GVHD:
-
chronic graftversus-host disease
- VP16:
-
etoposide
References
Atkinson K, Horowitz MM, Gale RP, Bekkum DW van, Gluckman E, Good RA, Jacobsen N, Kolb HJ, Rimm AA, Ringden O, Rozman C, Sobocinski KA, Zwaan FE, Bortin MM (1990) Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 75:2459–2464
Baum E, Nachman J, Ramsay N, Weetman B, Neerhout R, Littman P, Griffin T, Norris D, Sather H (1983) Prolonged second remissions in childhood acute lymphocytic leukaemia: a report from the childrens cancer study group. Med Pediatr Oncol 11:1–7
Birch JM (1983) Epidemiology of paediatric cancer, In: Duncan W (ed) Paediatric Oncology. Springer, Berlin Heidelberg New York, pp 1–10
Blaise D, Gaspard MH, Stoppa AM, Michel G, Gastaut JA, Lepeu G, Tubiana N, Blanc AP, Rossi JF, Novakovitch G, Mannoni P, Mavas C, Maraninchi D, Carcassonne Y (1990) Allogeneic or autologous bone marrow transplantation for acute lymphoblastic leukemia in first complete remission. Bone Marrow Transplant 5:7–12
Bleyer WA (1990) Acute lymphoblastic leukemia in children. Cancer 65:689–695
Brochstein JA, Kernan NA, Groshen S, Cirrincione C, Shank B, Emanuel D, Laver J, O'Reilly RJ (1987) Allogeneic bone marrow transplantation after hyperfractionated total-body irradiation and cyclophosphamide in children with acute leukemia. N Engl J Med 317:1618
Burchenal JH, Murphy ML (1965) Long-term survivors in acute leukaemia. Cancer Res 25:1491–1494
Colleselli P, Dini G, Andolina M, Bonetti F, Miniero R, Sonego M, Pigozzo P, Messina C, Forta F, Sotti G, Zanesco L (1991) Autologous bone marrow transplantation for acute lymphoblastic leukemia: the high dose vincristine study of AIEOP BMT group. Bone Marrow Transplatn 7 [Suppl 3]:28–30
Crist WM, Shuster JJ, Falletta J, Pullen DJ, Berard WC, Vietti TJ, Alvarado CS, Roper MA, Prasthofer E, Crossi CE (1988) Clinical features and outcome in childhood T-cell leukaemia-lymphoma according to stage of thymocyte differentiation. A Pediatric Oncology Group Study. Blood 72:1891
Crist W, Carroll A, Shuster J, Kackson J, Head D, Borowitz M, Behm F, Link M, Steuber P, Ragab A, Hirt A, Brock B, Land V, Pullen J (1990) Philadelphia chromosome positive childhood acute lymphoblastic leukemia: clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group study. Blood 76:489–494
Deeg HJ, Henslee-Downey PJ (1990) Management of acute graft-versus-host disease. Bone Marrow Transplant 6:1–8
Dopfer R, Henze G, Bender-Götze C, Ebell W, Ehninger G, Friedrich W, Gadner H, Klingebiel T, Peters C, Riehm H, Suttorp M, Schmid H, Schmitz N, Siegert W, Stollmann-Gibbels B, Hartmann R, Niethammer D (1991) Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study. Blood 78:2780–2784
Forman SJ, O'Donnell MR, Nademanee AP, Snyder DS, Bierman PJ, Schmidt GM, Fahey JL, Stein AS, Parker PM, Blume KG (1987) Bone marrow transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 70:587–588
Freeman AI, Weinberg V, Brecher ML, Jones B, Glicksman AS, Sinks LF, Weil M, Pleuss H, Hananian J, Burgert EO, Gilchrist GS, Necheless T, Harris M, Kung F, Patterson RB, Maurer H, Leventhal B, Chevalier L, Forman E, Holland JF (1983) Comparison of intermediate-dose methotrexate with cranial irradiation for the postinduction treatment of acute lymphocytic leukaemia in children. N Engl Med 308:477–484
Gasser C (1980) Long-term survival (cures) in childhood acute leukaemia. Paediatrician 9:344–357
Gaynon PS, Steinherz PS, Bleyer WA, et al (1988) Intensive therapy for children with acute lymphoblastic leukaemia and unfavourable presenting features. Lancet II:921–924
Goldstone AH, Souhami RL, Linch DC, Anderson CC, Harper PG, Machin S, Jellife (1984) Intensive Chemotherapy and autologous bone marrow transplantation for relapsed lymphoma. Exp Hematol 12:137
Gratwohl A, Hermans J, Barrett AJ, Ernst P, Frassoni F, Gahrton G, Granena A, Kolb HJ, Prentice HG, Vernant JP, Zwaan FE (1990) Allogeneic bone marrow transplantation for leukaemia in Europe: regional differences. Report from the leukaemia working party of the European Group for Bone marrow Transplantation. Bone Marrow Transplant 5:159–165
Gray R, Wheatley K, MRC Clinical Trial Service Unit (1991) How to avoid bias when comparing bone marrow transplantation with chemotherapy. Bone Marrow Transplant 7 [Suppl 3]: 9–12
Henze G, Fengler R, Hartmann R, Kornhuber B, Janka-Schaub G, Niethammer D, Riehm H (1991) Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-Rez BFM 85). A relapse study of the BFM group. Blood 78:1166–1172
Howard MR (1990) Strategies for selection of unrelate marrow donors. New Trends Ther Leuk Lymph 5:3–8
Howard MR, Hows JM, Gore SM, Bradley BA (1991) Unrelated donor marrow transplantation: an interim analysis of the International marrow unrelated search and transplant (IMUST) study II. Bone Marrow Transplant 7 [Suppl 2]:126
Ludwig WD, Seibt-Jung H, Teichmann JV, Komischke B, Gatzke A, Gassner G, Odenwald E, Hofmann J, Riehm H (1989) Clinicopathological features and prognostic implications of immunephenotypic subgroups in childhood ALL: experience of the BFM-ALL Study 83. In: Neth RD, et al (eds) Modern trends in human leukemia VIII. Springer, Berlin Heidelberg New York, pp 51–57
Ludwig WD, Thiel E, Löller U, Bartram CR, Harbott J, Teichmann JV, Seibt-Jung H, Creutzig U, Ritter J, Riehm H (1989) Incidence and clinical implications of acute hybrid leukemia in childhood. Hamatol Bluttransfus 33:516–522
Nesbit ME, Sather HN, Robinson LL, Ortega JA, Hammond GD, Children's Cancer Study Group (1983) Randomized study of 3 years versus 5 years of chemotherapy in childhood acute lymphoblastic leukaemia. J Clin Oncol 1:308–316
Niethammer D, Klingebiel T, Riehm H, Henze G, Schellong G, Bender-Götze C, Dopfer R, Ebell W, Friedrich W, Haas RJ, Schmitz N, Stollmann B (1991) Role and perspectives of BMT in ALL: the BFM experience. Bone Marrow Transplant 7 [Suppl 3]:14–18
Paolucci P, Dini G, Dallorso S, Meloni G, Locasciulli A, Andolina M, De Manzini A, Schettini F, Pession A (1991) Bone marrow transplantation in childhood: a report from the AIEOP-BMT group registry. Bone Marrow Transplant 7 [Suppl 3]:3–8
Philip T, Hartmann O, Biron P, Chan JY, Pein F, Bordigoni P, Souillet G, Gartner M, Lasset C, Chauvin F (1988) Highdose therapy and autologous bone marrow transplantation in partial remission after first-line induction therapy for diffuse non-Hodgkin's lymphoma. J Clin Oncol 6:1118–1124
Pui CH, Behm FG, Singh B, Rivera GK, Schell MJ, Roberts WM, Crist WM, Mirro J (1990) Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Blood 75:198–202
Pui CH, Carroll AJ, Raimondi SC, Land VJ, Crist WM, Shuster JJ, Williams DL, Pullen DJ, Borowitz MJ, Behm FG, Look AT (1990) Clinical presentation, karyotypic characterization, and treatment outcome of childhood acute lymphoblastic leukemia with a near-haploid or hypodiploid <45 line. Blood 75:1170–1177
Pui CH, Crist WM, Look T (1990) Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood 76:1449–1463
Ramsay NKC, Kersey JH (1990) Indications for marrow transplantation in acute lymphoblastic leukaemia. Blood 75:815–818
Reiter A, Schrappe M, Ludwig WD, Lampert F, Harbott J, Henze G, Niemeyer CM, Gadner H, Müller-Weihrich S, Ritter J, Odenwald E, Riehm H (1992) Favorable outcome of B-cell acute lymphoblastic leukemia (B-ALL) in childhood. A report of three consecutive studies of the BFM group. Blood (in press)
Riehm H, Gadner H, Henze G, Kornhuber B, Lampert F, Niethammer D, Reiter A, Schellong G (1990) Results and significance of six randomized trials in four consecutive ALL-BFM studies. Hamatol Bluttransfus 33:439–450
Sallan SE, Niemeyer CM, Billet AL, Lipton JM, Tarbel NJ, Gelber RD, Murray C, Pittinger TP, Wolfe LC, Bast RC, Ritz J (1989) Autologous bone marrow transplantation for acute lymphoblastic leukemia. J Clin Oncol 7:1594–1601
Slavin S, Ackerstein A, Naparstek E, Or R, Weiss L (1990) The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD? Bone Marrow Transplant 6:155–161
Thomas ED (1983) Bone marrow transplantation in malignant diseases. J Clin Oncol 1:517–531
Thomas ED, Buckner CD, Rudolph RH, Fefer A, Storb R, Neiman PE, Bryant JI, Chard RL, Clift RA, Epstein RB, Fialkow PJ, Funk DD, Giblett ER, Lerner KG, Reynolds FA, Slichter S (1971) Allogeneic marrow grafting for hematologic malignancy using HLA matched donor-recipient sibling pairs. Blood 38:276–287
Uckun KM, Kersey JH, Haake R, Weisdorf D, Ramsay KC (1992) Autologous bone marrow transplantation in high-risk remission B-lineage acute lymphoblastic leukemia using a cocktail of three monoclonal antibodies (BA-1/CD24, BA-2/CD9, and BA-3/CD10) plus complement and 4-hydroperoxycyclophosphamide for ex vivo bone marrow purging. Blood 79:1094–1104
Uderzo C, Coleselli P, Messina C, Dini G, Bonetti F, Andolina M, Bagnulo S, Miniero R, Rondelli R, Paoulucce P, Balduzzi A, Bonomi M, Locasciulli A (1991) Allogeneic BMT versus autologous BMT in childhood acute lymphoblastic leukemia (ALL): an Italian cooperative study of vincristine (VCR), F-TBI and cyclophosphamide. Bone Marrow Transplant 7 [Suppl 2]:132
Weisdorf DJ, McGlave PB, Ramsay NKC, Miller WJ, Nesbit ME, Woods WG, Goldman AI, Kim TH, Kersey JH (1988) Allogeneic bone marrow transplantation for acute leukaemia: comparative outcomes for adults and children. Br J Haematol 69:351–358
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Ebell, W., Reiter, A., Riehm, H. et al. Chemotherapy versus bone marrow transplantation in childhood acute lymphoblastic leukaemia. Eur J Pediatr 151 (Suppl 1), S50–S54 (1992). https://doi.org/10.1007/BF02125803
Issue Date:
DOI: https://doi.org/10.1007/BF02125803